| Gene symbol | PRAME | Synonyms | CT130, MAPE, OIP-4, OIP4 | Type of gene | protein-coding |
| Chromosome | 22 | Map location | 22q11.22 | dbXrefs | |
| Description | PRAME nuclear receptor transcriptional regulator | ||||
| GTO ID | GTC1981 |
| Trial ID | NCT03686124 |
| Disease | Solid Tumor |
| Altered gene | PRAME |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | IMA203;IMA203CD8 |
| HLA | HLA phenotype positive |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors |
| Year | 2018 |
| Country | United States|Germany |
| Company sponsor | Immatics US, Inc. |
| Other ID(s) | IMA203-101 |
| Cohort1: IMA203/IMA203CD8 | |||||||||
|
|||||||||
| Cohort2: IMA203/IMA203CD8_Nivolumab | |||||||||
|
|||||||||